Abstract:Uncontrolled expression of vascular endothelial growth factor (VEGF) in vivo may cause unexpected side effects, such as brain hemangioma or tumor growth. Because hypoxia-inducible factor-1 (HIF-1) is upregulated during cerebral ischemia and regulates gene expression by binding to a cis-acting hypoxia-responsive element (HRE), we therefore used a novel HRE, originating in the 3′-end of the erythropoietin (Epo) gene, to control gene expression in the ischemic brain. A concatemer of nine copies (H9) of the consensus sequence of HRE was used to mediate hypoxia induction. Three groups of adult CD-1 mice received AAVH9-VEGF, AAVH9-lacZ or saline injection, and then underwent 45 min of transient middle cerebral artery occlusion (tMCAO). Results show that HIF-1 was persistently expressed in the ischemic brain. VEGF was overexpressed in the ischemic perifocal region in AAVH9-VEGF-transduced mice. Double-labeled immunostaining showed that VEGF expressed in neurons and astrocytes but not endothelial cells, suggesting that adeno-associated virus (AAV) vectors transduced neurons and astrocytes predominantly. The total number of microvessels/enlarged microvessels was greatly increased in the AAVH9-VEGF-transduced mice (180±29/27±4) compared to the AAVH9-lacZ (118±19/14±3) or saline-treated (119±20/14±2) mice after tMCAO ( P <0.05). Cell proliferation examination demonstrated that these microvessels were newly formed. Regional cerebral blood flow recovery in the AAVH9-VEGF-transduced mice was also better than in AAVH9-lacZ or saline-treated mice ( P <0.05). Our data indicated that HRE is a novel trigger for the control of VEGF expression in the ischemic brain. VEGF overexpression through AAVH9-VEGF gene transfer showed stable focal angiogenic effects in post-ischemic repair process, providing an opportunity to rebuild injured brain tissue.

Adeno-Associated Virus Mediated Gene Therapy In Ischemic Stroke

Stimulation of cerebral angiogenesis by gene delivery.

Treatment of focal brain ischemia with viral vector-mediated gene transfer.

Highly Effective Stroke Therapy Enabled by Genetically Engineered Viral Nanofibers

Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases

Gene Therapy in Cerebrovascular Diseases

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications

Recombinant adeno-associated viral vector encoding human VEGF165 induces neomicrovessel formation in the adult mouse brain.

Adeno-associated Viral Vector-Mediated Hypoxia-Regulated VEGF Gene Transfer Promotes Angiogenesis Following Focal Cerebral Ischemia in Mice

A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases

Raav-Mediated Delivery Of Brain-Derived Neurotrophic Factor Promotes Neurite Outgrowth And Protects Neurodegeneration In Focal Ischemic Model

AAV-mediated gene therapy: Advancing cardiovascular disease treatment

Characteristics and Advantages of Adeno-Associated Virus Vector-Mediated Gene Therapy for Neurodegenerative Diseases

Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives.

637. Recombinant Adeno-Associated Viral Vector 2-Mediated Gene Transfer of VEGF Induces Neovascular Formation and Improves Blood Flow in Chronic Ischemic Swine Myocardium

Attenuation of Stroke Size in Rats Using an Adenoviral Vector to Induce Overexpression of Interleukin-1 Receptor Antagonist in Brain

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

Gene Delivery with Viral Vectors for Cerebrovascular Diseases

AAV-based in vivo gene therapy for neurological disorders

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy